Nebula Research & Development LLC Takes Position in Fulgent Genetics, Inc. (NASDAQ:FLGT)

Nebula Research & Development LLC purchased a new position in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 32,960 shares of the company's stock, valued at approximately $609,000. Nebula Research & Development LLC owned about 0.11% of Fulgent Genetics as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Geode Capital Management LLC lifted its holdings in Fulgent Genetics by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 514,152 shares of the company's stock valued at $9,499,000 after buying an additional 11,283 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Fulgent Genetics by 39.4% in the 4th quarter. JPMorgan Chase & Co. now owns 471,259 shares of the company's stock valued at $8,704,000 after purchasing an additional 133,215 shares during the period. Invesco Ltd. boosted its position in shares of Fulgent Genetics by 14.0% during the 4th quarter. Invesco Ltd. now owns 181,714 shares of the company's stock valued at $3,356,000 after purchasing an additional 22,301 shares in the last quarter. Barclays PLC grew its stake in Fulgent Genetics by 3.2% during the fourth quarter. Barclays PLC now owns 180,397 shares of the company's stock worth $3,332,000 after purchasing an additional 5,542 shares during the period. Finally, Trexquant Investment LP increased its holdings in Fulgent Genetics by 47.0% in the fourth quarter. Trexquant Investment LP now owns 128,606 shares of the company's stock worth $2,375,000 after purchasing an additional 41,147 shares in the last quarter. Institutional investors and hedge funds own 48.06% of the company's stock.

Insider Buying and Selling

In other news, CFO Paul Kim acquired 100,000 shares of the business's stock in a transaction on Wednesday, March 5th. The shares were purchased at an average cost of $15.96 per share, with a total value of $1,596,000.00. Following the acquisition, the chief financial officer now directly owns 348,282 shares of the company's stock, valued at $5,558,580.72. The trade was a 40.28 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 31.76% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several brokerages have recently commented on FLGT. StockNews.com raised shares of Fulgent Genetics from a "sell" rating to a "hold" rating in a research report on Wednesday, March 5th. Piper Sandler cut their price objective on shares of Fulgent Genetics from $22.00 to $16.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th.

Fulgent Genetics Stock Performance

Fulgent Genetics stock traded up $3.29 during mid-day trading on Friday, reaching $20.54. The stock had a trading volume of 851,635 shares, compared to its average volume of 266,165. The firm has a market capitalization of $633.99 million, a PE ratio of -3.72 and a beta of 1.36. Fulgent Genetics, Inc. has a fifty-two week low of $14.57 and a fifty-two week high of $25.11. The stock's 50-day simple moving average is $17.46 and its 200-day simple moving average is $18.07.

Fulgent Genetics (NASDAQ:FLGT - Get Free Report) last posted its quarterly earnings results on Friday, May 2nd. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.22. Fulgent Genetics had a negative net margin of 59.39% and a negative return on equity of 1.81%. The business had revenue of $73.46 million during the quarter, compared to the consensus estimate of $71.26 million. During the same quarter last year, the firm posted ($0.01) EPS. Fulgent Genetics's revenue was up 14.0% compared to the same quarter last year. On average, research analysts forecast that Fulgent Genetics, Inc. will post -0.85 earnings per share for the current fiscal year.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.